When was Javelin Pharmaceuticals founded?

Javelin Pharmaceuticals was founded in 1998 and raised its 1st funding round 7 years after it was founded.

Where is Javelin Pharmaceuticals located?

Javelin Pharmaceuticals is headquartered in Cambridge, United States.

Who is the current CEO of Javelin Pharmaceuticals?

Martin Driscoll of Javelin Pharmaceuticals.

How many employees does Javelin Pharmaceuticals have?

As of Mar 31, 2026, the latest employee count at Javelin Pharmaceuticals is 13.

Is Javelin Pharmaceuticals a funded company?

Javelin Pharmaceuticals is a funded company, having raised an undisclosed amount across 2 funding rounds to date. The company's 1st funding round was a $***** Conventional Debt round, raised on Nov 03, 2005.

How much is Javelin Pharmaceuticals worth?

The last known valuation of Javelin Pharmaceuticals was $***** as of Apr 19, 2010.

When was the latest funding round of Javelin Pharmaceuticals?

Javelin Pharmaceuticals' latest funding was a $***** Grant (prize money) round on Jul 07, 2006, with participation from 2 investors.

Where does Javelin Pharmaceuticals rank among its competitors?

Javelin Pharmaceuticals ranks 1003rd amongst 2708 active competitors, of which 908 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Erasca, which secured $45M in Mar, 2024.

Who are the top competitors of Javelin Pharmaceuticals?

Javelin Pharmaceuticals' top competitors include Jazz Pharmaceuticals, Sana Biotechnology and C4 Therapeutics. Among them, Erasca secured the most recent funding round in March, 2024.

Javelin Pharmaceuticals - 2026 Company Profile, Team, Funding & Competitors

Javelin Pharmaceuticals is an acquired company based in Cambridge (United States), founded in 1998 by Fred Mermelstein. It operates as a Pharma news, views, and analysis on medicine and pharmaceuticals. Javelin Pharmaceuticals has raised an undisclosed amount in funding, with last known valuation of $*****. The company has 2708 active competitors, including 908 funded and 684 that have exited. Its top competitors include companies like Jazz Pharmaceuticals, Sana Biotechnology and C4 Therapeutics.

Company Details

Pharma news, views, and analysis on medicine and pharmaceuticals. This platform delivers insights into the pharmaceutical industry, covering diseases, side effects, and treatments. It offers a range of articles and updates related to medicine, pharmaceuticals, and health. The website includes information on specific conditions like erectile dysfunction and bruxism. It serves as a resource for individuals seeking information on health-related topics, providing news, analysis, and views on the latest developments in the pharmaceutical and medical fields. The site also features a contact section and privacy policy for user convenience and transparency.

Website: javelinpharmaceuticals.com
Email ID: *****@javelinpharmaceuticals.com

Key Metrics

Founded Year

1998

Location

Cambridge, United States

Stage

Acquired

Latest Funding Round

Grant (prize money), Jul 07, 2006, $*****

Last Known Valuation

$***** as on Apr 19, 2010

Investors

Wexford Capital & 4 more

Ranked

1003^rd among 2708 active competitors

Employee Count

13 as on Mar 31, 2026

Similar Companies

Flexion Therapeutics & 298 more

Exit Details

Acquired by Hospira (Apr 19, 2010)

View Javelin Pharmaceuticals' full profile

Javelin Pharmaceuticals is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
Javelin Pharmaceuticals, Inc CIN: 880471759 , United States, Active	Dec 31, 1997	-	-	-

Javelin Pharmaceuticals got acquired by Hospira on Apr 19, 2010 at an acquisition amount of $*****.

Click here to take a look at Javelin Pharmaceuticals's acquisition in detail

Javelin Pharmaceuticals has raised funding over 2 rounds. Its first funding round was on Nov 03, 2005. Its latest funding round was a Grant (prize money) round on Jul 07, 2006 for $*****. 2 investors participated in its latest round. Javelin Pharmaceuticals has 5 institutional investors.

Here is the list of recent funding rounds of Javelin Pharmaceuticals:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Jul 07, 2006	6854604	Grant (prize money)	6515023	7077237	2172770	3915736
Nov 03, 2005	1257209	Conventional Debt	8330909	7715201	3515675	NGN Capital & 1 more

Access funding benchmarks and valuations. Sign up today!

View details of Javelin Pharmaceuticals's funding rounds and investors

The founders of Javelin Pharmaceuticals is Fred Mermelstein. Martin Driscoll is the CEO of Javelin Pharmaceuticals.

Here are the details of Javelin Pharmaceuticals' key team members:

Fred Mermelstein: Former Founder of Javelin Pharmaceuticals and founder of 1 other company.
Contact Info: 1 email address
Martin Driscoll: CEO of Javelin Pharmaceuticals.
Contact Info: 1 email address

View details of Javelin Pharmaceuticals's Founder profiles and Board Members

Javelin Pharmaceuticals' employee count trend

Javelin Pharmaceuticals has 13 employees as of Mar 26. Here is Javelin Pharmaceuticals's employee count trend over the years:

Employee count trend for Javelin Pharmaceuticals

Uncover Javelin Pharmaceuticals' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Javelin Pharmaceuticals include Jazz Pharmaceuticals, Sana Biotechnology and C4 Therapeutics. Here is the list of Top 10 competitors of Javelin Pharmaceuticals, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Prospect Venture Partners, Versant Ventures ... & 14 others	82/100
2nd	Sana Biotechnology 2018, Seattle (United States), Public	Developer of genetically engineered cell therapies for multiple disorders	$821M	Bezos Expeditions, Omega Funds & 17 others	75/100
3rd	C4 Therapeutics 2016, Cambridge (United States), Public	Developer of small molecule drugs for treating cancer	$223M	Cobro Ventures, Perceptive Advisors & 27 others	74/100
4th	Juno Therapeutics 2013, Seattle (United States), Acquired	Global biopharmaceutical company discovering, developing, and delivering innovative medicines	$317M	BB Biotech, Bezos Expeditions & 14 others	74/100
5th	Blueprint Medicines 2008, Cambridge (United States), Acquired	Developer of selective kinase inhibitors for patients with genomically defined cancers	$115M	Third Rock Ventures, Nextech Invest & 20 others	72/100
6th	argenx 2008, Ghent (Belgium), Public	Developer of antibody-based drugs to treat autoimmune diseases and cancer	$61.9M	Life Sciences Partners, Forbion & 20 others	72/100
7th	Kronos Bio 2017, San Mateo (United States), Acquired	Developer of small molecule based therapeutics for cancer treatment	$271M	Omega Funds, Vida Ventures & 18 others	72/100
8th	MacroGenics 2000, Rockville (United States), Public	Developer of novel biologics for the treatment of autoimmune disorders, cancer and infectious disease	$126M	Nextech Venture, Ventures West & 29 others	71/100
9th	Harbour BioMed 2016, Shanghai (China), Public	Developer of antibody therapeutics in immunology and oncology disease	$313M	Hudson Bay Capital, GIC & 19 others	71/100
10th	Erasca 2018, San Diego (United States), Public	Developer of small molecule based therapeutics for cancer	$300M	Cormorant Asset Management, Arch Venture Partners ... & 13 others	70/100
1003rd	Javelin Pharmaceuticals 1998, Cambridge (United States), Acquired	Pharma news, views, and analysis on medicine and pharmaceuticals	-	Wexford Capital, National Cancer Institute ... & 3 others	38/100